Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-small cell lung cancer (NSCLC) for decades with great success in patients with EGFR mutations, acquired resistance inevitably occurs after long-term exposure. More recently, combination therapy has emerged as a promising strategy to overcome this issue. Several experiments have been carried out to evaluate the synergism of combination therapy both in vitro and in vivo. Additionally, many clinical studies have been carried out to investigate the feasibility of treatment with EGFR-tyrosine kinase inhibitors (TKi) combined with other NSCLC treatments, including radiotherapy, cytotoxic chemotherapies, targeted therapies, and emerging immunotherapies. However, a significant gap still exists when applying pre-clinical results to clinical scenarios, which hinders the development and use of these strategies. This article is a literature review analysing the rationalities and controversies in the transition from pre-clinical investigation to clinical practice associated with various combination strategies. It also highlights clues and challenges regarding future combination therapeutic options in NSCLC treatment.
Introduction
Cancer is still one of the leading causes of death from illness, both in developed and developing countries [1] . Approximately 14.1 million newly diagnosed cases and 8.2 million deaths have been reported throughout the world according to the data set GLOBOCAN, which includes data on the annual increase in social medical burden [2] . Among all cancer types, lung cancer causes the highest number of cancer-related deaths in males, and is among the top five causes of cancer-related deaths in females [3] . In total, 1.8 million new cases of lung cancer were diagnosed in 2015, with a half of them living in underdeveloped areas [4] . Of note, in contrast to the decreasing incidence in Western countries, lung cancer diagnoses and death in China are still rising [5] , pointing to a tough and long road ahead to control the morbidity and mortality associated with lung cancer.
It has been reported that NSCLC contributes to over 80% of all lung cancer cases [6] . Platinum cytotoxic chemotherapy as well as radiotherapy emerged approximately half a century ago as therapeutic strategies for patients with NSCLC [7] . Although the application of those treatments with surgical operation was beneficial for some patients, by relieving pain, prolonging lifespan, and improving the quality of life [8] , the occurrence of adverse effects that not only killed cancer cells but also damaged the normal tissues and organs hampered the extensive application of those strategies [9] . With the development of individualised treatment, it has become well appreciated that lung cancer patients
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International Publisher with certain genetic backgrounds would benefit from targeted therapy [10] . EGFR is one of the members of the erbB family, a series of transmembrane growth factor receptor tyrosine kinase proteins, including erbB1 (EGFR), erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4) [11] . Approximately 30% to 40% of NSCLC patients harbour an EGFR mutation [6] , which promotes the constant phosphorylation of EGF receptors, activates downstream signalling pathways such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, and JAK-STAT, and in turn confers cancer cell proliferation and survival [12] . Therefore, targeting EGFR is a promising therapeutic strategy for NSCLC patients with an EGFR mutation, which have been highly successful in recent decades [13] .
Unfortunately, acquired resistance to EGFR-TKi treatment, where lung cancer cells become insensitive to those inhibitors after a long period of treatment, almost inevitably occurs [14] . Possible mechanisms for the acquired resistance have been extensively discussed. Appearance of second-site hot spot mutations that partially contributed to the acquired resistance, such as T790M [15] , D761Y [16] , and T854A [17] , with T790M being the most common alteration, led to the discovery of the third-generation EGFR-TKis, such as AZD9291 [18] and CO-1686 [19] . Other mechanisms leading to resistance not involving EGFR mutations included the bypass signalling activation such as the amplification of mesenchymal-epithelial transition (MET) [20] , a type of human hepatocyte growth factor receptor that is essential for embryonic development, organogenesis, and wound healing, or a mutation in the PI3K pathway [21] found in some NSCLC patients who did or did not undergo EGFR inhibitor treatment. Occurrence of epithelial-mesenchymal transition (EMT) was reported to confer acquired resistance to EGFR targeted therapy [22] . Combination strategy has been suggested as a promising method not only to overcome resistance but also to reduce the dosages of both agents to minimise adverse effects and enhance the anti-cancer effect of individual strategies [23] . The current review summarises EGFR-TKi combinations for treating NSCLC, including radiotherapy, chemotherapy, targeted therapy, and emerging immunotherapy. The focus is on both clinical outcomes and pre-clinical evaluations, to analyse the pros and cons of various combination strategies and to elucidate clues for future therapeutic options in clinical practice.
EGFR-TKi combined with radiotherapy
Radiotherapy is widely used in the treatment of NSCLC [24] . It is usually used as an adjuvant treatment postoperatively. However, for patients with locally advanced NSCLC who cannot undergo surgery, radiotherapy combined with chemotherapy is helpful [24] . The rationale of administering EGFR-TKi with radiotherapy is based on the involvement of EGFR overexpression or mutation in radio-resistant cases of NSCLC. Chinnaiyan et al. [25] reported the synergistic anti-cancer effect of erlotinib combined with radiotherapy in UM-SCC6 and H226 human NSCLC cell lines via attenuating cell clonogenic survival and in vivo tumour growth. These effects appeared to be attributed to the addition of erlotinib to radiation therapy, which induced cell apoptosis, inhibited EGFR activation, overexpressed Rad51, and enhanced other signalling mediators, such as Egr-1, IL-1β, and CXCL1 [25] . Kim et al. [26] found EGFR expression in three different NSCLC cell lines to be positively correlated with sensitivity to EGFR-TKi treatment, but to be negatively correlated to radio-sensitivity. They found that the involvement of erlotinib could not only increase G1 cell cycle arrest in those cell lines, but also promote cell apoptosis in A431 [26] . Michael et al. [27] summarised several pre-clinical studies and addressed various combination mechanisms apart from above-mentioned ones, including inactivating cancer stem cells directly to improve local tumour control, modulating several signalling pathways, suppressing DNA repair, decreasing cell repopulation, and improving re-oxygenation, all of which provided valid evidences for clinical practice. Several trials have tested the combination of EGFR-TKi and radiotherapy, and some have reported that the combination would be feasible, tolerated, and effective in certain populations of patients [28] , indicating that the use of the combination should be determined individually for specific cases based on the patient's genetic background.
Besides chest irradiation, local radiotherapy limited to the brain region is a treatment option for NSCLC patients with brain metastasis, which includes 20% to 40% of all NSCLC cases [29] . These patients account for a large proportion of NSCLC-associated deaths. The brain-blood barrier (BBB), which restricts the ability of systematic chemotherapeutic agents and EGFR-TKi to reach the cerebrospinal fluid (CSF) [30] , can be damaged when brain metastasis occurs. The resultant leakage of the BBB in turn improves the penetration ability of these agents or inhibitors, which could be applied together with whole-brain radiotherapy (WBRT) [31] . Many clinical trials have reported the availability of WBRT combined with EGFR-TKi for patients with brain metastasis. Cai et al. [32] found that, compared with radiotherapy alone, the addition of EGFR-TKi significantly increased patients' progression-free survival (PFS) and overall survival (OS 
EGFR-TKi in combination with chemotherapy
In the past, patients who suffered from various types of cancer significantly benefited from classical cytotoxic drug chemotherapy, administered either simultaneously with surgery to increase the success of the operation or continuously in unresectable cases to control the progression of diseases and improve the patient's quality of life [8] . Chemotherapy is still recommended as the first-line therapy in NSCLC patients without defined therapeutic targets [40] , although several treatments combining chemotherapy and EGFR-TKi are under development.
Platinum-based chemotherapy (cisplatin or carboplatin) is often used to treat NSCLC [7] , whereas its combination with EGFR-TKi showed mixed results in both pre-clinical studies and in clinical trials. Lee et al. [41] indicated that a combination of low-dose erlotinib and cisplatin may exert a synergistic effect in NSCLC cell lines that contain an EGFR exon 19 deletion, which is probably due to an anti-angiogenesis effect via targeting c-myc/HIF-1α/VEGF signalling. However, a meta-analysis that included 191 randomised phase II trials concluded that the combination of erlotinib plus carboplatin and paclitaxel did not have a significant beneficial effect on PFS and OS but rather showed more severe adverse effects compared to erlotinib alone, regardless of the EGFR status [42] . Furthermore, Tsai et al. [43] reported that the failure of the TKi-platinum combination was probably due to the antagonistic effect of the two compounds, as EGFR-TKi can interfere with the absorption of cisplatin. Liu et al. [44] demonstrated that the inhibition of autophagy could improve the synergism of the gefitinib-cisplatin combination. Future studies will probably reveal the reason for the failure to translate these "promising" pre-clinical results into clinical effects, and provide possible solutions that will allow these combination therapies to be used in clinical practice ( Figure. 1 ).
Gemcitabine is another cytotoxic agent used in NSCLC therapy. It has been reported that the combination of gemcitabine and AG1478, an EGFR-TKi, produces a synergistic anti-cancer effect depending on the level of ERK activation as well as KRAS status [45] . Nonetheless, a multicentre, randomised, open-label phase trial showed that sequentially delivered erlotinib and gemcitabine did not provide beneficial effects to patients over gemcitabine alone [46] . A recent systematic analysis summarised a number of clinical trials of combination therapy using EGFR-TKi together with various cytotoxic chemotherapeutic agents and concluded that the combination is not superior to either agent alone for the first-line treatment of NSCLC [47] . Thus, further studies are required to determine the possible effectiveness and mechanisms of combination therapy.
Pemetrexed has recently been developed to suppress the metabolism of intracellular folic acid, and thus prevent cell division [48] . It has significant activity and favourable tolerance as well as low toxicity when compared to other cytotoxic agents, and has been well studied for administration either alone or in combination [48] . A combination of pemetrexed and EGFR-TKi has been highly touted to overcome EGFR-TKi-acquired resistance. In their study, Wu et al. [49] illustrated that the synergistic anti-cancer effect of the combination can only be found in the EGFR-TKi resistant PC9/GR cell line and not in the EGFR-TKi sensitive PC9 cell line, with a possible mechanism of inducing cell apoptosis and suppressing AKT as well as ERK phosphorylation in synergy. La Monica et 
EGFR-TKi combined with targeted therapy
Although classical cytotoxic chemotherapy has been widely used for decades, the relief of cancer burden is usually accompanied with significant adverse effects, such as myelosuppression, in most cases [56] . Therefore, targeted therapy was developed to treat the disease with fewer side effects. This approach has achieved tremendous success in the last two decades in specific groups of patients, holding the promise of emerging personalised medicine [57] . 
Anti-VEGFR2 agents
Vascular endothelial growth factor receptor 2 (VEGFR2), one of the subunits of the VEGFR family, is strongly associated with angiogenesis which plays a key role in tumour progression and metastasis [60] . As micro-vessel count was reported to be an independent prognostic predictor of NSCLC [61], targeting VEGFR2 should be a promising strategy for NSCLC treatment. Bevacizumab is a promising antibody for blocking VEGFR2, and is used in combination with EGFR-TKi as the first-line treatment for NSCLC [62] . Li et al. [63] found that the addition of bevacizumab to EGFR-TKi in NSCLC xenografts enhanced the TKi concentration in tumour samples with high levels of VEGF protein, the direct ligand of VEGFR2, suggesting that the combination of targeting EGFR and VEGFR2 may produce a synergistic anti-cancer effect. Clinical data have shown that the combination may be significantly beneficial for patients with specific genetic backgrounds. An open-label, randomised, multicentre, phase II study showed a significant extension of PFS in patients with EGFR-mutation positive when treated with erlotinib plus bevacizumab compared with erlotinib alone [64] . Although the results of another phase II trial failed to meet its primary goal, it showed that the combination of gefitinib and bevacizumab resulted in longer PFS in the sub-group of patients with an EGFR-sensitive mutation of exon 19 Overexpression of HER2, another member of the erbB family, is also found in various types of cancer including NSCLC, and is associated with a poor clinical outcome [83] . Pre-clinical studies have found that the amplification of HER2 in NSCLC enhanced sensitivity to treatment with gefitinib via the inhibition of HER2/HER3 heterodimer formation [84] , implying the possibility of combination therapy with the addition of an anti-HER2 antibody to EGFR-TKi treatment. Nakamura et al. [85] found that the combination of gefitinib and trastuzumab, the well-known anti-HER2 antibody, exerted a synergistic effect on cell proliferation attenuation through co-suppression of EGFR downstream signalling in the NSCLC cell line A549, which is driven by EGFR/HER2 heterodimers, but not in NCI-H23, which is controlled by other factors or receptors. 
Anti-EGFR downstream agents
The disruption in EGFR downstream signalling has also been shown to contribute to the acquired resistance of NSCLC to EGFR-TKi therapy [ 
MET inhibitors
MET receptors, which transduce several downstream signalling targets that mediates the process of cell survival and proliferation, including MAPK, PI3K, STAT, and NF-kB, have been widely discussed as potential targets in cancer therapy [114] . Puri et al. [115] found that stimulation of EGF and HGF simultaneously in NSCLC cell lines promoted tumour cell growth and downstream signalling activation. Zhang et al. [116] reported that the overexpression of MET led to increased EGFR phosphorylation via EGFR heterodimerisation, whereas suppression of both MET and EGFR produced synergistic anti-cancer effects both in vitro and in vivo by inhibiting downstream signalling. These results point to a promising approach for treating NSCLC via targeting both MET and EGFR. The effectiveness of targeted therapy involving EGFR-TKi combinations in pre-clinical studies is based on specific genetic alterations or on bypassing signal activation [130] . Nevertheless, the reasons for the failure of translating those strategies into clinical practice include, but are not limited to the following: the differences in the tumour microenvironment between humans and animals, or between in vivo and in vitro conditions [131] , and the integrity of the tumour's internal environment, from which the tumour cannot be completely overcome via suppression of one or two individual genes or pathways [132] . The more we know about these differences, the more we will be able to make the right decisions and promote successful therapeutic effects for specific patients (Figure 1 ).
EGFR-TKi combined with immunotherapy
Recently, immunotherapy has become the most popular option for cancer treatment [133] . Unlike targeted therapy, which produces direct anti-tumour effects by blocking specific signalling pathways that are over-activated in cancer, the goal of immunotherapy is to stimulate in vivo immune cells to kill tumour cells that have escaped from previous immunological surveillance [134] . The antibodies used in immunotherapy are larger, which are highly specific and selectively bind their target receptors than those used in targeted therapy [135] . Therefore, they have potent anti-cancer effects. Application of large molecules for immunotherapy will become widely available, as many antibodies have been approved for NSCLC treatment [136, 137] ; meanwhile, the combination of immunotherapy with targeted therapy is also under evaluation [138] .
The programmed death 1 (PD-1) pathway and its key ligand, the programmed death ligand 1 (PD-L1) have emerged in recent years as key targets for NSCLC therapy. 
Conclusions and Perspectives
For patients with NSCLC who harbour EGFR mutations, marketed EGFR-TKis (Table 1) are the first-line strategy recommended in the NCCN guidelines [40] . It will remain the preferred option for a long period until a better choice emerges. Therefore, acquired resistance will be one of the most challenging issues to overcome. Even for the new-generation EGFR-TKis, they are not insusceptible to acquired resistance [149] . Mechanism of drug actions for various kinds of combination strategies have been reported in pre-clinical studies. As shown in Figure 2 , these can be broadly summarised as: 1 sensitivity [63, 76] . However, it is rare that these pre-clinical reported "promising" combination strategies can be translated into clinical practice successfully, suggesting the mechanisms of drug actions discovered in pre-clinical studies are unlikely to pertain to the clinical situations. Clearly, biomedical scientists and physicians should work closely to rationalise the gaps between pre-clinical results and clinical outcomes. In the foreseeable future, radiotherapy and chemotherapy will still be used as adjuvant or neoadjuvant therapy to combine with EGFR-TKi in cases of advanced, refractory, or metastatic NSCLC as long as the effectiveness can be validated in clinical trials. The use of combined targeted therapy with EGFR-TKi should be case dependent, as diverse signalling activation will be developed differently in different patients. A comprehensive application of chip-based diagnose techniques, next-generation sequencing, and immunohistochemistry to monitor potential biomarkers in circulation or in tumour samples will be helpful to determine and provide appropriate treatment options for specific cases. For combination therapy involving immunotherapy, it is crucial to avoid the increased adverse effects caused by the administration of antibodies, which is a problem awaiting detailed mechanistic elucidation. Therefore, it is important to find out the sub-population with the best response to the combination therapy.
Moreover, development of alternative strategies should be encouraged, in addition to the previous options, to cure individual NSCLC cases. Targeting tumour metabolism is one of the emerging and promising strategies for cancer treatment recently, which refers to the therapeutic modulations of the specific process of energy metabolism that cancer cells adopted, namely metabolising glucose through the anaerobic glycolysis rather than the normal mitochondrial oxidative phosphorylation (OXPHOS) even in normoxia conditions [150] . 160] , both of which are PDK inhibitors. Further investigations will be required to understand the mechanism of drug actions, which could facilitate the development of this combination strategy to overcome the resistance to EGFR-TKi treatment.
Last but not the least, retrospective studies should be performed to analyse not only the activity or toxicity of the combination but also the categorisation of patient subgroups with the aim to select patients that are likely to be benefited from combination therapy in terms of cost-effectiveness, extended lifespan, and improved quality of life. 
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